Biopeople asked Tomasz K. Wojdacz, PhD, CEO of the company MethylDetect ApS to answer some basic questions about the company and what it does. MethylDetect’s ambition is to bring our technology enabling cost effective in-vitro diagnostic detection of methylation biomarkers into routine use in clinical disease management. Read more at: https://biopeople.eu/news/show/september-profile-methyldetect/